Beta Bionics, Inc. faces a proposed investor lawsuit over disclosures about its iLet insulin-delivery system, following findings by the Food and Drug Administration on complaint handling and reporting.
The complaint, filed Sept. 4 in the U.S. District Court for the Central District of California, names the company, Chief Executive Officer Sean Saint and Chief Financial Officer Stephen Feider as defendants. It covers people who bought or acquired Beta Bionics common stock from July 30, 2025, through Feb. 24, 2026. The suit alleges that statements about iLet’s safety, efficacy and commercial prospects misled investors and violated federal securities laws. The FDA describes iLet as a system that includes the iLet Dosing Decision Software and iLet ACE Pump.
The FDA’s Jan. 28 warning letter followed an inspection of the company’s Irvine facility from June 9 to June 26, 2025. The agency said 107 complaints involving severe hypoglycemia, or steps to prevent it, were submitted as serious-injury reports. It also said Beta Bionics closed 56 related complaints without corrective action.
The FDA cited more than 500 complaints about cartridge or connector leaks from June 2023 through June 2025. The agency said the company closed 31 without investigating them; 18 of those complaints described hyperglycemic effects.
In a Jan. 30 filing with the Securities and Exchange Commission, Beta Bionics said the warning letter did not restrict its ability to make or distribute products and that it had taken some corrective actions. In a separate securities filing, the company said it intended to defend against the lawsuit and that any potential loss was not then probable or estimable.
The allegations have not been proven, and the court has not certified the proposed class. Hagens Berman’s Oct. 16 notice identifies Nov. 3, 2026, as the deadline to seek appointment as lead plaintiff.
